ATE336997T1 - Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen - Google Patents

Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen

Info

Publication number
ATE336997T1
ATE336997T1 AT99970022T AT99970022T ATE336997T1 AT E336997 T1 ATE336997 T1 AT E336997T1 AT 99970022 T AT99970022 T AT 99970022T AT 99970022 T AT99970022 T AT 99970022T AT E336997 T1 ATE336997 T1 AT E336997T1
Authority
AT
Austria
Prior art keywords
fulvic acid
treatment
medical conditions
various medical
condition
Prior art date
Application number
AT99970022T
Other languages
English (en)
Inventor
Johannes Dekker
Constance Elizabeth Medlen
Original Assignee
Pfeinsmith Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfeinsmith Ltd filed Critical Pfeinsmith Ltd
Application granted granted Critical
Publication of ATE336997T1 publication Critical patent/ATE336997T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99970022T 1998-10-08 1999-10-08 Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen ATE336997T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA989190 1998-10-08
ZA992848 1999-04-21

Publications (1)

Publication Number Publication Date
ATE336997T1 true ATE336997T1 (de) 2006-09-15

Family

ID=27144980

Family Applications (4)

Application Number Title Priority Date Filing Date
AT06012244T ATE410159T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von candida infektionen
AT99970022T ATE336997T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
AT06012245T ATE410160T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von entzündungen
AT06012243T ATE410158T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von viralen infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06012244T ATE410159T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von candida infektionen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06012245T ATE410160T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von entzündungen
AT06012243T ATE410158T1 (de) 1998-10-08 1999-10-08 Fulvinsäure und deren verwendung in der behandlung von viralen infektionen

Country Status (7)

Country Link
US (1) US6569900B1 (de)
EP (4) EP1126837B1 (de)
JP (1) JP4700808B2 (de)
AT (4) ATE410159T1 (de)
AU (1) AU766198B2 (de)
DE (4) DE69939722D1 (de)
WO (1) WO2000019999A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570565C (en) * 2004-06-23 2012-10-23 Bioz Agri Products Inc. Method for extracting fulvic acid molecules
RU2280458C1 (ru) * 2004-11-30 2006-07-27 Алевтина Ивановна Косолапова Противовоспалительная мазь
WO2006064449A1 (en) * 2004-12-15 2006-06-22 Van Der Westhuizen Cornelis Fl Detoxifying and immunity-booster composition
US20080160111A1 (en) * 2005-02-28 2008-07-03 Hiroko Isoda Type I Allergy Inhibitor and Methods of Inhibiting the Onset of Type I Allergy Using Fulvic Acid
JP2006232785A (ja) * 2005-02-28 2006-09-07 Univ Of Tsukuba フルボ酸を用いるｉ型アレルギー抑制剤及びｉ型アレルギーの発症抑制方法。
US20070212434A1 (en) * 2006-03-07 2007-09-13 Day Kenneth S Compositions and methods for human use containing fulvic acid
CN101437509B (zh) 2006-05-02 2012-03-14 皮费恩史密斯有限公司 酸性组合物
US8445452B2 (en) 2008-06-05 2013-05-21 Pfeinsmith Ltd. Fulvic acid and antibiotic combination
DE102008058552A1 (de) 2008-11-21 2010-05-27 Mankau, Dieter, Prof. Dr. Federrahmen und Federkörper zur Abstützung z. B. einer Matratze
GB0900786D0 (en) * 2009-01-19 2009-03-04 Natracine Uk Ltd Therapeutic compositions
GB0914966D0 (en) * 2009-08-27 2009-09-30 Natracine Uk Ltd Fulvic acid compositions and their use
WO2013023062A1 (en) * 2011-08-09 2013-02-14 Wilford Lynn C Antimicrobial agents and methods for use thereof in the abatement of food borne pathogenic organisms
MY170829A (en) 2012-03-07 2019-09-05 Pfeinsmith Ltd Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria
WO2014193338A1 (en) 2013-05-28 2014-12-04 Empire Technology Development Llc Humic acid derivatives and methods of preparation and use
EP3004070B1 (de) 2013-05-28 2017-10-11 Empire Technology Development LLC Antioxidative huminsäurederivate sowie verfahren zur herstellung und verwendung
WO2014209369A1 (en) 2013-06-28 2014-12-31 Empire Technology Development Llc Edible plasticizers for food and food packaging films
WO2017102565A1 (en) * 2015-12-15 2017-06-22 Rita Dobmeyer Pharmaceutical composition comprising a fulvic acid and at least one boron-containing compound
US9820953B2 (en) 2016-02-26 2017-11-21 Omni Bioceutical Innovations, Inc. Compositions of bioactive fulvate fractions and uses thereof
JP6120342B1 (ja) * 2016-03-08 2017-04-26 株式会社スタイルアンドバリュージャパン 美容組成物
CN113924084A (zh) * 2019-03-20 2022-01-11 瑞塔·多布迈尔 药物组合物
EP3799854A1 (de) 2019-10-01 2021-04-07 Stefan Johannes Fellner Extrakt von organischen humifizierten materialien
WO2021226627A1 (en) * 2020-05-05 2021-11-11 Figene, Llc Reduction of cytokine storm and pathological inflammation including caused by coronavirus using sphagnum and extracts thereof
KR102258006B1 (ko) * 2020-12-22 2021-05-28 허교 풀빅산을 유효성분으로 포함하는 항바이러스 조성물
CN117064913A (zh) * 2023-02-23 2023-11-17 单士军 用于缓解特应性皮炎的黄腐酸外用制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB244215A (en) 1924-10-09 1925-12-17 Richard William Bailey Improvements in or relating to gas or oil power plant
DE2850685A1 (de) * 1978-11-22 1980-06-04 Kneer Franz X Verfahren zur herstellung eines kolloiden schlammbades und schlammartiger pasten fuer die heilbehandlung
US5204368A (en) * 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
JPH0466508A (ja) * 1990-07-03 1992-03-02 Suntory Ltd 抗菌剤
JPH0687752A (ja) * 1992-09-04 1994-03-29 Kyowa Kagaku Kogyo Kk 抗菌水及びこの抗菌水の製造方法
CN1097990A (zh) * 1994-01-29 1995-02-01 康宏盛 一种治疗股癣的药物
JPH1017483A (ja) * 1996-06-26 1998-01-20 Keinzu Corp:Kk 皮膚疾患予防及び治療剤
JP2001501899A (ja) * 1996-06-27 2001-02-13 オルガノフロ（プロプリータリ）リミテッド 液体肥料物質の製造方法
JPH119674A (ja) * 1997-06-25 1999-01-19 M S K Planning:Kk フミン酸を有効成分とする液体消臭剤と、その製造方法及びフミン酸を有効成分とした飲料用消臭剤と、その製造方法
CN1103339C (zh) * 1998-08-25 2003-03-19 祝亚勤 药用级泥炭黄腐植酸钠的制备方法

Also Published As

Publication number Publication date
AU766198B2 (en) 2003-10-09
EP1700600A1 (de) 2006-09-13
JP4700808B2 (ja) 2011-06-15
EP1700599A1 (de) 2006-09-13
DE69939721D1 (de) 2008-11-20
ATE410159T1 (de) 2008-10-15
EP1700600B1 (de) 2008-10-08
AU5992399A (en) 2000-04-26
DE69932939D1 (de) 2006-10-05
ATE410158T1 (de) 2008-10-15
DE69939720D1 (de) 2008-11-20
JP2002526407A (ja) 2002-08-20
DE69932939T2 (de) 2006-12-07
US6569900B1 (en) 2003-05-27
ATE410160T1 (de) 2008-10-15
EP1126837B1 (de) 2006-08-23
EP1698333B1 (de) 2008-10-08
EP1700599B1 (de) 2008-10-08
EP1698333A1 (de) 2006-09-06
EP1126837A1 (de) 2001-08-29
WO2000019999A1 (en) 2000-04-13
DE69939722D1 (de) 2008-11-20

Similar Documents

Publication Publication Date Title
ATE336997T1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE69108048D1 (de) Derivate von hydroxaminsäure und von n-hydroxyharnstoff sowie ihre verwendung.
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE336255T1 (de) Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben
EP1192949A4 (de) Azneimittel mit chymaseinhibitoren als wirksames mittel, zur vorbeugung oder behandlung von fibrosis
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ATE185803T1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
ATE271896T1 (de) Salbe enthaltend mometason-furoat und salicylsäure zur topischen behandlung von psoriasis
DE69906532D1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat
BR0014751A (pt) Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto
RU94041246A (ru) Способ лечения псориаза
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties